165 related articles for article (PubMed ID: 38503143)
1. Viewing the immune checkpoint VISTA: landscape and outcomes across cancers.
Nishizaki D; Kurzrock R; Miyashita H; Adashek JJ; Lee S; Nikanjam M; Eskander RN; Patel H; Botta GP; Nesline MK; Pabla S; Conroy JM; DePietro P; Sicklick JK; Kato S
ESMO Open; 2024 Apr; 9(4):102942. PubMed ID: 38503143
[TBL] [Abstract][Full Text] [Related]
2. The Expression Pattern and Clinical Significance of the Immune Checkpoint Regulator VISTA in Human Breast Cancer.
Xie X; Zhang J; Shi Z; Liu W; Hu X; Qie C; Chen W; Wang Y; Wang L; Jiang J; Liu J
Front Immunol; 2020; 11():563044. PubMed ID: 33250890
[TBL] [Abstract][Full Text] [Related]
3. LAG-3, TIM-3 and VISTA Expression on Tumor-Infiltrating Lymphocytes in Oropharyngeal Squamous Cell Carcinoma-Potential Biomarkers for Targeted Therapy Concepts.
Wuerdemann N; Pütz K; Eckel H; Jain R; Wittekindt C; Huebbers CU; Sharma SJ; Langer C; Gattenlöhner S; Büttner R; Speel EJ; Suchan M; Wagner S; Quaas A; Klussmann JP
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396515
[TBL] [Abstract][Full Text] [Related]
4. V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma.
Muller S; Victoria Lai W; Adusumilli PS; Desmeules P; Frosina D; Jungbluth A; Ni A; Eguchi T; Travis WD; Ladanyi M; Zauderer MG; Sauter JL
Mod Pathol; 2020 Feb; 33(2):303-311. PubMed ID: 31537897
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoints and cancer development: Therapeutic implications and future directions.
Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
[TBL] [Abstract][Full Text] [Related]
6. Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study.
Shi X; Li CW; Tan LC; Wen SS; Liao T; Zhang Y; Chen TZ; Ma B; Yu PC; Lu ZW; Qu N; Wang Y; Shi RL; Wang YL; Ji QH; Wei WJ
J Clin Endocrinol Metab; 2021 Jan; 106(1):120-132. PubMed ID: 33000173
[TBL] [Abstract][Full Text] [Related]
7. Expression of the immune checkpoint VISTA in breast cancer.
Zong L; Mo S; Yu S; Zhou Y; Zhang M; Chen J; Xiang Y
Cancer Immunol Immunother; 2020 Aug; 69(8):1437-1446. PubMed ID: 32266446
[TBL] [Abstract][Full Text] [Related]
8. Expression and Prognostic Value of B7 Family Immune Checkpoints in Pancreatic Neuroendocrine Tumors.
Mo S; Zong L; Chen X; Ban X; Li M; Lu Z; Yu S; Chen J
Arch Pathol Lab Med; 2023 Feb; 147(2):193-201. PubMed ID: 35671167
[TBL] [Abstract][Full Text] [Related]
9. The dynamic role of immune checkpoint molecules in diagnosis, prognosis, and treatment of head and neck cancers.
Mestiri S; El-Ella DMA; Fernandes Q; Bedhiafi T; Almoghrabi S; Akbar S; Inchakalody V; Assami L; Anwar S; Uddin S; Gul ARZ; Al-Muftah M; Merhi M; Raza A; Dermime S
Biomed Pharmacother; 2024 Feb; 171():116095. PubMed ID: 38183744
[TBL] [Abstract][Full Text] [Related]
10. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.
Qin S; Xu L; Yi M; Yu S; Wu K; Luo S
Mol Cancer; 2019 Nov; 18(1):155. PubMed ID: 31690319
[TBL] [Abstract][Full Text] [Related]
11. Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome.
Araujo B de Lima V; Borch A; Hansen M; Draghi A; Spanggaard I; Rohrberg K; Reker Hadrup S; Lassen U; Svane IM
Cytotherapy; 2020 Apr; 22(4):204-213. PubMed ID: 32201034
[TBL] [Abstract][Full Text] [Related]
12. The immune checkpoint VISTA exhibits high expression levels in human gliomas and associates with a poor prognosis.
Ghouzlani A; Lakhdar A; Rafii S; Karkouri M; Badou A
Sci Rep; 2021 Nov; 11(1):21504. PubMed ID: 34728682
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of immune checkpoint molecules in breast cancer.
Fang J; Chen F; Liu D; Gu F; Chen Z; Wang Y
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32602545
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Protein Expression Defines the Prognosis of Advanced Thyroid Carcinoma.
Luo Y; Yang YC; Shen CK; Ma B; Xu WB; Wang QF; Zhang Y; Liao T; Wei WJ; Wang Y
Front Endocrinol (Lausanne); 2022; 13():859013. PubMed ID: 35574031
[TBL] [Abstract][Full Text] [Related]
15. VISTA immune regulatory effects in bypassing cancer immunotherapy: Updated.
Mortezaee K; Majidpoor J; Najafi S
Life Sci; 2022 Dec; 310():121083. PubMed ID: 36265568
[TBL] [Abstract][Full Text] [Related]
16. VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer.
Zong L; Zhou Y; Zhang M; Chen J; Xiang Y
Cancer Immunol Immunother; 2020 Jan; 69(1):33-42. PubMed ID: 31781843
[TBL] [Abstract][Full Text] [Related]
17. Immune related endonucleases and GTPases are not associated with tumor response in patients with advanced non-small cell lung cancer treated with checkpoint inhibitors.
Ramdani HO; Falk M; Heukamp LC; Schatz S; Tiemann M; Wesseler C; Diehl L; Schuuring E; Groen HJM; Griesinger F
Pathol Res Pract; 2021 Nov; 227():153651. PubMed ID: 34673351
[TBL] [Abstract][Full Text] [Related]
18. Clinical Insights Into Novel Immune Checkpoint Inhibitors.
Lee JB; Ha SJ; Kim HR
Front Pharmacol; 2021; 12():681320. PubMed ID: 34025438
[TBL] [Abstract][Full Text] [Related]
19. Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity.
Kato S; Okamura R; Kumaki Y; Ikeda S; Nikanjam M; Eskander R; Goodman A; Lee S; Glenn ST; Dressman D; Papanicolau-Sengos A; Lenzo FL; Morrison C; Kurzrock R
Oncoimmunology; 2020; 9(1):1708065. PubMed ID: 32117584
[TBL] [Abstract][Full Text] [Related]
20. Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules.
D'Arrigo P; Tufano M; Rea A; Vigorito V; Novizio N; Russo S; Romano MF; Romano S
Curr Med Chem; 2020; 27(15):2402-2448. PubMed ID: 30398102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
